Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price fell 8.7% during trading on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $73.00 and last traded at $73.4740. 2,311,550 shares were traded during trading, an increase of 17% from the average session volume of 1,975,592 shares. The stock had previously closed at $80.48.

The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same period in the prior year, the business earned $1.26 earnings per share. The company’s revenue for the quarter was up 51.6% on a year-over-year basis.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record full‑year revenue and strong forward guidance — Halozyme reported 2025 total revenue of $1.397B (up 38% YoY) and reiterated 2026 guidance calling for $1.71–$1.81B in revenue, a sharply higher adjusted EBITDA range and $7.75–$8.25 non‑GAAP EPS guidance, which supports longer‑term revenue growth expectations. HALO FY2025 Results & Guidance
• Positive Sentiment: Royalty momentum and strategic technology acquisitions — Royalty revenue reached a record ~$868M (up ~52% YoY) and Halozyme completed acquisitions (Hypercon technologies) that management says will broaden product/enhancer applications, supporting recurring royalty upside. Royalty Growth & Acquisitions
• Neutral Sentiment: Q4 revenue beat but watch accounting/one‑offs — Q4 revenue of $451.8M modestly topped consensus, and slides/transcript provide detail that much of the story is royalty mix and GAAP items — investors should read the earnings deck/transcript to assess how much of the EPS swing is non‑recurring. Yahoo — Q4 Highlights
• Neutral Sentiment: Investor resources available — Management’s slide deck and full earnings transcript are posted (useful for modelling royalty cadence, margin drivers, and the components of the EPS miss). Earnings Presentation
• Negative Sentiment: Surprise quarterly loss / large EPS miss — Halozyme reported GAAP EPS of ($0.24) vs. consensus near $1.90+ (wide miss), with an operating loss and net loss driven by higher cost of sales and other items; that shock to EPS is the main catalyst for the selloff. Earnings Call Transcript
• Negative Sentiment: Wider operating loss, rising liabilities and cash dynamics — Q4 showed an operating loss and a notable rise in total liabilities; while cash increased modestly, investors are focused on margin pressure and how recurring royalty growth offsets cost trends. QuiverQuant Financial Highlights
• Negative Sentiment: Recent insider selling and mixed analyst positioning — Large insider sales disclosed in filings and a range of analyst price targets (median ~$84.5 but with some lower targets) add to near‑term uncertainty and pressure on the stock. Insider & Analyst Notes

Analyst Ratings Changes

Several research firms have weighed in on HALO. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. TD Cowen increased their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $77.44.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 49,398 shares of company stock worth $3,650,592. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of the company. DLD Asset Management LP bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $650,250,000. Norges Bank bought a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $128,201,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $124,031,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after purchasing an additional 1,082,638 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 8.8%

The firm’s 50 day moving average is $71.55 and its two-hundred day moving average is $70.25. The firm has a market capitalization of $8.63 billion, a P/E ratio of 15.50, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.